Federal officials to hold Tamaqua public meeting July 9 about polycythemia vera research plans

The U.S. Agency for Toxic Substances and Disease Registry, the troubled Centers for Disease Control and Prevention subdivision that's investigating a Hometown-area cluster of the rare blood cancer polycythemia vera, will hold a public meeting this Thursday, July 9 to discuss how it plans to spend the $5.5 million Congress allocated for the official study into the problem, which researchers believe is environmental in origin.



The meeting will take place from 7 to 9 p.m. at the Tamaqua Area High School auditorium. The ATSDR's press release about the event, posted below in full, says it will provide "an overview of the PV research and other activities that will be funded by a special appropriation. In addition, the principal investigators of three already-identified projects will be on hand for more detailed discussions of their work. The projects include: the Drexel epidemiological study, the McAdoo Superfund Site Water Outflow Study, and the ATSDR JAK2 screening project."

Please note that while the headline says the test indicating whether a person has the JAK2 genetic mutation associated with polycythemia vera is "to be available for area residents," blood draws will in fact be done in August and not at this week's meeting.

* * *

ATSDR Slates July 9 Public Meeting on Polycythemia Vera Issues - JAK2 Testing to Be Available for Area Residents

Carbon, Luzerne, Schuylkill County County, Tamaqua, Pennsylvania

Tuesday, June 30, 2009

ATLANTA - The federal Agency for Toxic Substances and Disease Registry (ATSDR) will hold a public meeting in the Tamaqua High School auditorium, 500 Penn St, Tamaqua, PA., on Thursday, July 9, 2009 from 7:00 to 9:00 p.m. to inform area residents of recent efforts regarding polycythemia vera (PV).

At the meeting ATSDR officials will present an overview of the PV research and other activities that will be funded by a special appropriation. In addition, the principal investigators of three already-identified projects will be on hand for more detailed discussions of their work. The projects include: the Drexel epidemiological study, the McAdoo Superfund Site Water Outflow Study, and the ATSDR JAK2 screening project.

The JAK2 genetic marker was discovered in 2004 and found to occur in more than 95% of PV patients. Many experts believe people with PV and related blood disorders may test positive for the JAK2 marker for a number of years before ever exhibiting symptoms of PV. It is not known at this time if the JAK2 marker always leads to PV or another blood disease.

Since the rates of PV are higher in this area of Pennsylvania than other parts of the state, ATSDR will offer free blood tests to the community for the purpose of screening for the JAK2 gene marker. By volunteering for this testing, residents can learn if they carry this marker, even though they are currently without symptoms of PV. Early diagnosis and treatment of PV can prevent or delay complications.

Individuals aged 40 or older are deemed most likely to test positive for the JAK2 marker; however, anyone living in Carbon, Luzerne or Schuylkill County is eligible for the screening. Blood draw clinics will be set up in Hazelton, Tamaqua and Pottsville from August 3-6 and August 10-13, 2009. Individuals are encouraged to make an appointment ahead of time by signing up at the public meeting or by calling 1-877-525-4860.

MEDIA NOTICE: A media availability session with the presenters and ATSDR officials will be held on site prior to the start of the public session from 6:00 to 6:45 p.m.

ATSDR, a federal public health agency of the U.S. Department of Health and Human Services, evaluates the human health effects of exposure to hazardous substances.